As a consequence, prevention of IL-6 activity by specific neutralizing antibodies or STAT3 inhibitors may represent another potential research area of new therapeutic agents to prevent lipolysis, brown adipocyte conversion, and cancer-associated cachexia. Here, STAT3 is linked to cancer.